Instructions for Orungamin (Itraconazole)
English product name
Orungamin
Release form
Capsules
Description Orungamin:
Capsules are solid gelatine, size №0, body is transparent, blue-colored cap is opaque; The capsule contents are white or almost white spherical pellets.
1 cap.
Itraconazole* 100 mg
Itraconazole pellet (22%) - 455 mg.
Ingredients per 1000 g of pellets: active substance: Itraconazol - 220 mg;
auxiliary substances: sucrose - 117.05 g, sucrose (sucrose, starch molasses) - 347.19 g, hypromellose - 280.53 g, methylparahydroxybenzoate sodium - 0.165 g, propyl parahydroxybenzoate sodium - 0.015 g, eudragite E-100 - 35.05 g
Capsule body composition: gelatin - up to 100%.
Capsule cap composition: dye indigocarmine - 0.0471%, titanium dioxide - 1%, gelatin - up to 100%.
4 pcs. - packages of box contour (1) - cardboard packs.
7 pcs. - packages of box contour (2) - cardboard packs.
14 pcs. - box-type contour (3) packages - cardboard packs.
ATC codes
J02AC02 Itraconazole
Clinical-pharmacological groups / Group affiliation
Antifungal preparation
Active substance
Itraconazole
Pharmacotherapy group
Antifungal agent
Storage Conditions
The drug should be stored in a place inaccessible to children, protected from light at a temperature not higher than 25 ° C.
Best before date
Shelf life is 3 years. Do not apply after expiry date.
Testimony Orungamin:
- skin and mucous membranes lesions:
- dermatomycosis;
- vulvovaginal candidiasis;
- The cut-off;
- Oral mucosa candidiasis;
- fungal keratitis.
- onychomycosis caused by dermatophytes and/or yeast-like fungi;
- systemic mycosis:
- systemic aspergillosis and candidiasis;
- cryptococcosis, including cryptococcal meningitis (in immunocompromised patients and in all cryptococcal patients of the CNS, Itraconazole should only be prescribed if first-line drugs are not applicable or effective);
- histoplasmosis;
- sporotrichoz;
- paracocydiidomycosis;
- blastomycosis;
- other rarely occurring systemic or tropical mycosis.
Method of use, course and dosage:
The drug is taken inside, immediately after eating. Capsules should be swallowed whole.
Display Dose Duration
Vulvovaginal candidiasis 200 mg twice/day or 200 mg once/day 1 day or 3 days
Red-headed fox 200 mg once/day seven days
Dermatomycosis smooth skin 200 mg 1 time/day or 100 mg 1 time/day 7 days or 15 days
Lesions of highly keratinized skin areas such as hands and feet 200 mg 2 times/day or 100 mg 1 times/day 7 days or 30 days
Oral mucosa candidiasis 100 mg once/day 15 days
Fungal keratitis 200 mg once/day 21 days. Correction of treatment duration is possible taking into account positive dynamics of clinical picture
The bioavailability of Itraconazole during ingestion may be reduced in some immunocompromised patients, such as neutropenia patients, AIDS patients, or transplant patients. In such cases, a double dose increase may be required.
Onychomycosis caused by dermatophytes and/or yeast-like and mold fungi
Pharmacological effect Orungamin:
Antifungal agent. Itraconazole is a broad-spectrum synthetic antifungal agent derived from triazole. Inhibits the synthesis of ergosterol cell membrane of fungi, which causes the antifungal effect of the preparation. Itraconazole is active in relation to: Trichophyton spp, Microsporum spp, Epidermophyton floccosum, Candida spp yeast fungi. (including Candida albicans, Candida parapsilosis), mold fungi
